Previous 10 | Next 10 |
MINNEAPOLIS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pa nbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the European Medicines Agency (EMA) Committee for ...
MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced its first patients enrolled in Europe for its ASPIRE ...
Panbela Therapeutics, Inc. (PBLA) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - CEO Susan Horvath - CFO Conference Call Participants Tony Butler - ROTH Capital P...
Panbela Therapeutics press release ( NASDAQ: PBLA ): Q3 GAAP EPS of -$0.21. Total cash was $0.9 million as of September 30, 2022. Total current assets were $1.8million and current liabilities were $8.0 million as of the same date. For further details see: Panbela...
MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the qu...
MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA ), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 10, 2...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com Pre-market stock movers continue to be a major topic as we dive into the latest news investors need to know about on Friday! Moving stocks are a reverse split, earnings reports,...
Panbela Therapeutics (NASDAQ: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, has released the pricing of its public offering. The public offering is comprised of 20,100,000 shares of its common stock (or pre...
MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA ) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced today that management will participate in the inaugural Ro...
Panbela Therapeutics ( NASDAQ: PBLA ) prices a public offering of (i) 20.1M shares of stock, warrants to purchase up to 30.15M shares at a purchase price of $0.30. Warrants will have an exercise price of $0.30 per share, are exercisable upon issuance, and will expire five ...
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
Panbela Therapeutics Inc Com Website:
DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged Survival Rapid Enrollment P...
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference,...
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the q...